Randomized Evaluation of the Loss-of-function Carboxylesterase 1 (CES1) G143E Variant on Clopidogrel and Ticagrelor Pharmacodynamics

Overview

Journal Clin Transl Sci

Specialties Biomedical Engineering
General Medicine

Date 2024 Nov 22

PMID 39576732

Authors

Joshua P Lewis

Kathleen A Ryan

Elizabeth A Streeten

Hilary B Whitlatch

Melanie Daue

Keith Tanner

James A Perry

Jeffrey R OConnell

Alan R Shuldiner

Braxton D Mitchell

Affiliations

Soon will be listed here.

Abstract

Antiplatelet therapy with a P2Y receptor inhibitor, in combination with aspirin, is standard of care for medical management of patients with coronary artery disease, and flexibility in prescribing options among these medications offers great potential for individualizing patient care. Previously, we showed that a loss-of-function missense mutation (G143E) in carboxylesterase 1 (CES1), the primary enzyme responsible for clopidogrel degradation, significantly impacts on-clopidogrel platelet aggregation and recurrent cardiovascular event risk. In the current investigation, we conducted a prospective randomized crossover study of clopidogrel (75 mg/day for 7 days) and ticagrelor (180 mg/day for 7 days) in 50 individuals stratified by CES1 G143E genotype (N = 34 143GG and 16 143GE) to determine the effect of drug choice on inhibition of platelet aggregation (IPA). Consistent with prior reports, we observed strong association between G143E and adenosine diphosphate-stimulated platelet aggregation following clopidogrel administration (IPA = 71.6 vs. 48.0% in 143E-allele carriers vs. non-carriers, respectively, p = 3.8 × 10). Similar significant effects on platelet aggregation were also noted between 143E-allele carriers versus non-carriers in response to stimulation with arachidonic acid (45.8 vs. 25.8%, p = 0.04), epinephrine (44.4 vs. 18.8%, p = 0.03), and collagen (5 μg/mL, 25.8 vs. 11.4%, p = 3.7 × 10). In contrast, no relationship between CES1 G143E and IPA was observed following ticagrelor administration regardless of the platelet agonist used. Collectively, these data suggest that on-clopidogrel platelet aggregation is substantially modified by CES1 G143E genotype, that this variant does not modify ticagrelor pharmacodynamics, and that more consistent inhibition of platelet aggregation may be achieved by using ticagrelor in patients who carry clopidogrel response-modifying alleles in CES1.

References

Shi J, Wang X, Nguyen J, Bleske B, Liang Y, Liu L . Dabigatran etexilate activation is affected by the CES1 genetic polymorphism G143E (rs71647871) and gender. Biochem Pharmacol. 2016; 119:76-84. PMC: 5061634. DOI: 10.1016/j.bcp.2016.09.003. View

Her L, Zhu H . Carboxylesterase 1 and Precision Pharmacotherapy: Pharmacogenetics and Nongenetic Regulators. Drug Metab Dispos. 2019; 48(3):230-244. PMC: 7031766. DOI: 10.1124/dmd.119.089680. View

Teng R, Oliver S, Hayes M, Butler K . Absorption, distribution, metabolism, and excretion of ticagrelor in healthy subjects. Drug Metab Dispos. 2010; 38(9):1514-21. DOI: 10.1124/dmd.110.032250. View

Zhu H, Markowitz J . Activation of the antiviral prodrug oseltamivir is impaired by two newly identified carboxylesterase 1 variants. Drug Metab Dispos. 2008; 37(2):264-7. DOI: 10.1124/dmd.108.024943. View

Karczewski K, Francioli L, Tiao G, Cummings B, Alfoldi J, Wang Q . The mutational constraint spectrum quantified from variation in 141,456 humans. Nature. 2020; 581(7809):434-443. PMC: 7334197. DOI: 10.1038/s41586-020-2308-7. View

Loucks C, Lin J, Trueman J, Drogemoller B, Wright G, Chang W . Patient-specific genetic factors predict treatment failure in sofosbuvir-treated patients with chronic hepatitis C. Liver Int. 2022; 42(4):796-808. DOI: 10.1111/liv.15175. View

Kuliczkowski W, Witkowski A, Polonski L, Watala C, Filipiak K, Budaj A . Interindividual variability in the response to oral antiplatelet drugs: a position paper of the Working Group on antiplatelet drugs resistance appointed by the Section of Cardiovascular Interventions of the Polish Cardiac Society, endorsed by the.... Eur Heart J. 2009; 30(4):426-35. DOI: 10.1093/eurheartj/ehn562. View

Williams E, Jones K, Ponsler G, Lowery S, Perkins E, Wrighton S . The biotransformation of prasugrel, a new thienopyridine prodrug, by the human carboxylesterases 1 and 2. Drug Metab Dispos. 2008; 36(7):1227-32. DOI: 10.1124/dmd.107.020248. View

Lee C, Luzum J, Sangkuhl K, Gammal R, Sabatine M, Stein C . Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2C19 Genotype and Clopidogrel Therapy: 2022 Update. Clin Pharmacol Ther. 2022; 112(5):959-967. PMC: 9287492. DOI: 10.1002/cpt.2526. View

10.

Tarkiainen E, Holmberg M, Tornio A, Neuvonen M, Neuvonen P, Backman J . Carboxylesterase 1 c.428G>A single nucleotide variation increases the antiplatelet effects of clopidogrel by reducing its hydrolysis in humans. Clin Pharmacol Ther. 2015; 97(6):650-8. DOI: 10.1002/cpt.101. View

11.

Zhu H, Wang X, Gawronski B, Brinda B, Angiolillo D, Markowitz J . Carboxylesterase 1 as a determinant of clopidogrel metabolism and activation. J Pharmacol Exp Ther. 2013; 344(3):665-72. DOI: 10.1124/jpet.112.201640. View

12.

Gurbel P, Antonino M, Tantry U . Recent developments in clopidogrel pharmacology and their relation to clinical outcomes. Expert Opin Drug Metab Toxicol. 2009; 5(8):989-1004. DOI: 10.1517/17425250903107772. View

13.

Lian J, Bahitham W, Panigrahi R, Nelson R, Li L, Watts R . Genetic variation in human carboxylesterase CES1 confers resistance to hepatic steatosis. Biochim Biophys Acta Mol Cell Biol Lipids. 2018; 1863(7):688-699. DOI: 10.1016/j.bbalip.2018.04.002. View

14.

Zhu H, Appel D, Jiang Y, Markowitz J . Age- and sex-related expression and activity of carboxylesterase 1 and 2 in mouse and human liver. Drug Metab Dispos. 2009; 37(9):1819-25. DOI: 10.1124/dmd.109.028209. View

15.

Backman J, Yerges-Armstrong L, Horenstein R, Newcomer S, Shaub S, Morrisey M . Prospective Evaluation of Genetic Variation in Platelet Endothelial Aggregation Receptor 1 Reveals Aspirin-Dependent Effects on Platelet Aggregation Pathways. Clin Transl Sci. 2017; 10(2):102-109. PMC: 5355965. DOI: 10.1111/cts.12438. View

16.

Friedrichsen M, Poulsen P, Wojtaszewski J, Hansen P, Vaag A, Rasmussen H . Carboxylesterase 1 gene duplication and mRNA expression in adipose tissue are linked to obesity and metabolic function. PLoS One. 2013; 8(2):e56861. PMC: 3585247. DOI: 10.1371/journal.pone.0056861. View

17.

Xie H, Zou J, Hu Z, Zhang J, Ye F, Chen S . Individual variability in the disposition of and response to clopidogrel: pharmacogenomics and beyond. Pharmacol Ther. 2010; 129(3):267-89. DOI: 10.1016/j.pharmthera.2010.10.001. View

18.

Li H, Zhang Z, Weng H, Qiu Y, Zubiaur P, Zhang Y . Association between rs2244613 and the pharmacokinetics and safety of dabigatran: Meta-analysis and quantitative trait loci analysis. Front Cardiovasc Med. 2022; 9:959916. PMC: 9386138. DOI: 10.3389/fcvm.2022.959916. View

19.

Vistoli G, Pedretti A, Mazzolari A, Bolchi C, Testa B . Influence of ionization state on the activation of temocapril by hCES1: a molecular-dynamics study. Chem Biodivers. 2009; 6(11):2092-100. DOI: 10.1002/cbdv.200900174. View

20.

Arena De Souza V, Scott D, Nettleship J, Rahman N, Charlton M, Walsh M . Comparison of the Structure and Activity of Glycosylated and Aglycosylated Human Carboxylesterase 1. PLoS One. 2015; 10(12):e0143919. PMC: 4676782. DOI: 10.1371/journal.pone.0143919. View